Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676310 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
A Phase 1 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02676310 is a Phase 1 study that was terminated before completion, run by Allergan. The registered enrollment target is 53 participants.
The verdict
NCT02676310, a Phase 1 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
Interventions
- DRUG Bimatoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676310
The ClinicalTrials.gov registry entry for NCT02676310 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimatoprost is the first listed.
NCT02676310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676310 about?
NCT02676310 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)". This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
What is the current status of trial NCT02676310?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2016-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02676310?
The interventions under investigation include: Bimatoprost (DRUG).
Who is sponsoring clinical trial NCT02676310?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.